Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Background Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/...

Full description

Saved in:
Bibliographic Details
Main Authors: Dina M Flink, Se Jeong, Gavin Thurston, Rajat Bannerji, Vladimir Jankovic, Nathalie Fiaschi, Max S Topp, Jurriaan Brouwer-Visser, Raquel P Deering, Kamil J Cygan, Darius Scott, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Johannes Duell, Ranjana H Advani, Aafia Chaudhry, Srikanth R Ambati
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/3/e008338.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/3/e008338.full

Similar Items